These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 16421508)

  • 1. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
    Bohnen NI; Albin RL; Koeppe RA; Wernette KA; Kilbourn MR; Minoshima S; Frey KA
    J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
    Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
    Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
    Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
    JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of
    Sanchez-Catasus CA; Bohnen NI; Yeh FC; D'Cruz N; Kanel P; Müller MLTM
    J Nucl Med; 2021 Apr; 62(4):545-552. PubMed ID: 32859707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease.
    Martin WR; Wieler M; Stoessl AJ; Schulzer M
    Ann Neurol; 2008 Mar; 63(3):388-94. PubMed ID: 18240153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
    J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
    Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
    Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased striatal monoaminergic terminals in Huntington disease.
    Bohnen NI; Koeppe RA; Meyer P; Ficaro E; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
    Neurology; 2000 May; 54(9):1753-9. PubMed ID: 10802780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal dopaminergic and free-water imaging in Parkinson's disease.
    Yang J; Archer DB; Burciu RG; Müller MLTM; Roy A; Ofori E; Bohnen NI; Albin RL; Vaillancourt DE
    Parkinsonism Relat Disord; 2019 May; 62():10-15. PubMed ID: 30639168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
    Lin KJ; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Hsiao IT
    PLoS One; 2013; 8(9):e75952. PubMed ID: 24098749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative study of
    Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
    Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
    Yagi S; Yoshikawa E; Futatsubashi M; Yokokura M; Yoshihara Y; Torizuka T; Ouchi Y
    J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
    Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
    Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased Striatal Vesicular Monoamine Transporter Type 2 Correlates With the Nonmotor Symptoms in Parkinson Disease.
    Shi X; Zhang Y; Xu S; Kung HF; Qiao H; Jiang L; Zhu L; Guo Q; Yi C; Luo G; Wu L; Pei Z; Wang J; Zhang X; Chen L
    Clin Nucl Med; 2019 Sep; 44(9):707-713. PubMed ID: 31205154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.